Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270945 · ClinicalTrials.gov registry record · Phase 2
Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.
A Phase 2 study of Patients Undergoing Repeat Peripheral Artery Revascularization, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 8
- Study locations
NCT01270945 is a Phase 2 study of Patients Undergoing Repeat Peripheral Artery Revascularization that has completed, run by Janssen Research & Development. The registered enrollment target is 43 participants. The trial reports 8 study locations across 5 states.
The verdict
NCT01270945, a Phase 2 study of Patients Undergoing Repeat Peripheral Artery Revascularization, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine if CV-18C3 will reduce the rate of restenosis or the time to restenosis in patients undergoing repeat peripheral artery revascularization versus controls randomized to standard of care.
Conditions Studied
Interventions
- PROCEDURE Standard of Care
- DRUG CV-18C3
Study Locations (8)
Florida
- JFK Medical Center - Atlantis
- River City Clinical Research - Jacksonville
- Jacksonville Center for Clinical Research - Jacksonville
- Mediquest Research Group - Ocala
California
- Sutter Heart & Vascular Institute - Sacramento
Georgia
- John D. Archbold Memorial Hospital - Thomasville
Ohio
- Univeristy of Cincinnati University Hospital - Cincinnati
Texas
- Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-06-30 |
| Est. Completion | 2014-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01270945
The ClinicalTrials.gov registry entry for NCT01270945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients Undergoing Repeat Peripheral Artery Revascularization appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT01270945 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01270945 about?
NCT01270945 is a clinical study titled "Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.". The purpose of this study is to determine if CV-18C3 will reduce the rate of restenosis or the time to restenosis in patients undergoing repeat peripheral artery revascularization versus controls randomized to standard of care.
What is the current status of trial NCT01270945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2011-06-30. Estimated completion is 2014-04-30.
What conditions does trial NCT01270945 study?
This clinical trial studies the following conditions: Patients Undergoing Repeat Peripheral Artery Revascularization.
What interventions are being tested in trial NCT01270945?
The interventions under investigation include: Standard of Care (PROCEDURE), CV-18C3 (DRUG).
Who is sponsoring clinical trial NCT01270945?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01270945 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.